BioCentury
ARTICLE | Company News

FDA accepts CPI-300 NDA

June 24, 2009 12:16 AM UTC

IntelGenx Corp. (TSX-V:IGX; OTCBB:IGXT) said FDA accepted for review an NDA from partner Cary Pharmaceuticals Inc. (Great Falls, Va.) for CPI-300 to treat major depressive disorder. The PDUFA date is ...